PAH patients have decreased levels of apolipoprotein E (ApoE), a factor that reduces circulating low-density lipoprotein (LDL), and consequently, atherogenesis, and decreased levels of PPARg in the lungs, and this was associated with decreased levels of adiponectin, leading to IR. Here, PPARG is linked to pulmonary arterial hypertension.